BRPI0613999B8 - uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto - Google Patents
uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produtoInfo
- Publication number
- BRPI0613999B8 BRPI0613999B8 BRPI0613999A BRPI0613999A BRPI0613999B8 BR PI0613999 B8 BRPI0613999 B8 BR PI0613999B8 BR PI0613999 A BRPI0613999 A BR PI0613999A BR PI0613999 A BRPI0613999 A BR PI0613999A BR PI0613999 B8 BRPI0613999 B8 BR PI0613999B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- combination
- product
- pharmaceutical composition
- quinoline
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 206010062207 Mycobacterial infection Diseases 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 abstract 1
- -1 quinoline derivative compound Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05105755.2 | 2005-06-28 | ||
| EP05105755 | 2005-06-28 | ||
| PCT/EP2006/063552 WO2007000434A1 (en) | 2005-06-28 | 2006-06-26 | Quinoline derivatives as antibacterial agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0613999A2 BRPI0613999A2 (pt) | 2011-03-01 |
| BRPI0613999B1 BRPI0613999B1 (pt) | 2020-04-22 |
| BRPI0613999B8 true BRPI0613999B8 (pt) | 2021-05-25 |
Family
ID=35447198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0613999A BRPI0613999B8 (pt) | 2005-06-28 | 2006-06-26 | uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20130030016A1 (enExample) |
| EP (1) | EP1898909B1 (enExample) |
| JP (1) | JP5193857B2 (enExample) |
| KR (1) | KR101329587B1 (enExample) |
| CN (1) | CN101252927B (enExample) |
| AP (1) | AP2547A (enExample) |
| AR (1) | AR054804A1 (enExample) |
| AU (1) | AU2006263882B2 (enExample) |
| BR (1) | BRPI0613999B8 (enExample) |
| CA (1) | CA2612614C (enExample) |
| CY (1) | CY1119402T1 (enExample) |
| DK (1) | DK1898909T3 (enExample) |
| EA (1) | EA014431B1 (enExample) |
| ES (1) | ES2610472T3 (enExample) |
| HR (1) | HRP20170044T1 (enExample) |
| HU (1) | HUE030264T2 (enExample) |
| IL (1) | IL188395A (enExample) |
| JO (1) | JO3322B1 (enExample) |
| LT (1) | LT1898909T (enExample) |
| MX (1) | MX2008000079A (enExample) |
| MY (1) | MY173664A (enExample) |
| NO (1) | NO341285B1 (enExample) |
| NZ (1) | NZ564340A (enExample) |
| PL (1) | PL1898909T3 (enExample) |
| PT (1) | PT1898909T (enExample) |
| RS (1) | RS55601B1 (enExample) |
| SG (1) | SG166798A1 (enExample) |
| TW (1) | TWI413520B (enExample) |
| UA (1) | UA88701C2 (enExample) |
| WO (1) | WO2007000434A1 (enExample) |
| ZA (1) | ZA200711148B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2752B1 (en) | 2005-06-28 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO2970B1 (en) | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JP5397881B2 (ja) * | 2008-09-04 | 2014-01-22 | 昇一 城武 | グラム陽性細菌用抗菌剤及び抗菌活性増強剤 |
| CN104254527B (zh) | 2012-04-27 | 2017-05-31 | 詹森药业有限公司 | 抗菌的喹啉衍生物 |
| AU2013254670B2 (en) | 2012-04-27 | 2017-03-30 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| JP7514763B2 (ja) * | 2017-10-13 | 2024-07-11 | ザ ユニバーシティー オブ クイーンズランド | 亜鉛イオノフォアおよびその使用 |
| CN110606825A (zh) * | 2019-10-30 | 2019-12-24 | 成都海杰亚医药科技有限公司 | 一种制备吡啶-2-硫醇的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| DK2301544T3 (da) * | 2002-07-25 | 2013-01-02 | Janssen Pharmaceutica Nv | Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer |
| EP1753427B1 (en) * | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| EE05697B1 (et) * | 2005-06-08 | 2014-02-17 | Janssen Pharmaceutica N.V. | Kinoliini derivaadid kui antibakteriaalsed toimeained |
-
2006
- 2006-06-26 DK DK06763888.2T patent/DK1898909T3/en active
- 2006-06-26 AP AP2008004298A patent/AP2547A/xx active
- 2006-06-26 EP EP06763888.2A patent/EP1898909B1/en active Active
- 2006-06-26 ES ES06763888.2T patent/ES2610472T3/es active Active
- 2006-06-26 HR HRP20170044TT patent/HRP20170044T1/hr unknown
- 2006-06-26 PL PL06763888T patent/PL1898909T3/pl unknown
- 2006-06-26 EA EA200800151A patent/EA014431B1/ru unknown
- 2006-06-26 UA UAA200714928A patent/UA88701C2/ru unknown
- 2006-06-26 RS RS20170045A patent/RS55601B1/sr unknown
- 2006-06-26 SG SG201007976-2A patent/SG166798A1/en unknown
- 2006-06-26 MX MX2008000079A patent/MX2008000079A/es active IP Right Grant
- 2006-06-26 HU HUE06763888A patent/HUE030264T2/en unknown
- 2006-06-26 JP JP2008518809A patent/JP5193857B2/ja not_active Expired - Fee Related
- 2006-06-26 CA CA2612614A patent/CA2612614C/en active Active
- 2006-06-26 PT PT67638882T patent/PT1898909T/pt unknown
- 2006-06-26 WO PCT/EP2006/063552 patent/WO2007000434A1/en not_active Ceased
- 2006-06-26 KR KR1020087002246A patent/KR101329587B1/ko not_active Expired - Fee Related
- 2006-06-26 NZ NZ564340A patent/NZ564340A/en not_active IP Right Cessation
- 2006-06-26 AU AU2006263882A patent/AU2006263882B2/en not_active Ceased
- 2006-06-26 LT LTEP06763888.2T patent/LT1898909T/lt unknown
- 2006-06-26 MY MYPI20063021A patent/MY173664A/en unknown
- 2006-06-26 BR BRPI0613999A patent/BRPI0613999B8/pt not_active IP Right Cessation
- 2006-06-26 CN CN200680031302.9A patent/CN101252927B/zh not_active Expired - Fee Related
- 2006-06-27 AR ARP060102758A patent/AR054804A1/es unknown
- 2006-06-27 TW TW095123049A patent/TWI413520B/zh not_active IP Right Cessation
- 2006-06-29 JO JOP/2006/0183A patent/JO3322B1/ar active
-
2007
- 2007-12-20 ZA ZA2007/11148A patent/ZA200711148B/en unknown
- 2007-12-25 IL IL188395A patent/IL188395A/en active IP Right Grant
-
2008
- 2008-01-28 NO NO20080499A patent/NO341285B1/no not_active IP Right Cessation
-
2012
- 2012-08-07 US US13/568,569 patent/US20130030016A1/en not_active Abandoned
-
2017
- 2017-01-18 CY CY20171100071T patent/CY1119402T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0413452A (pt) | composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv | |
| BRPI0720220B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
| BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| UY30759A1 (es) | Compuestos quimicos | |
| CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| BR112012017269A2 (pt) | compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos | |
| BRPI0810064B8 (pt) | compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos | |
| JOP20190142B1 (ar) | مركبات 7-فينيل إيثيل أمينو-4h-بيريميدو[4، 5-d] وبيريدو[4، 3-d]-1، 3-أكسازين-2-ون كمثبطات idh1 وidh2 الطافر | |
| BRPI0915084B8 (pt) | composto, e, composição farmacêutica | |
| BRPI0815920A2 (pt) | Composto, composição farmacêutica, e, uso do composto. | |
| UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
| BR112015027704A2 (pt) | Composto, uso do mesmo e composição farmacêutica antibacteriana | |
| CL2008003406A1 (es) | Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih. | |
| EA200970081A1 (ru) | Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения | |
| GEP20156370B (en) | Fluoro-pyridinone derivatives useful as antibacterial agents | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| BRPI0721905B8 (pt) | composto inibidor de proteassoma, sua composição farmacêutica e seu uso | |
| BR112014009415A2 (pt) | inibidores de arginase e suas aplicações terapêuticas | |
| BRPI0716171A8 (pt) | Composto, composição farmacêutica e uso de um composto | |
| BRPI0412291A (pt) | antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia | |
| UY30544A1 (es) | Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones | |
| CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
| DOP2009000165A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| BR112014002958A2 (pt) | "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso". | |
| GEP20135959B (en) | Aryl piperazine and their usage as alpha2c antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/04/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2780 DE 16-04-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |